Application of the AJCC-8 criteria can be expected to simplify the staging process for most DTC patients, who will now be classified as ‘younger’. It will also markedly reduce the number of patients with a substantial mortality risk (those with stages III–IV disease, where the DSS-10 is <50–70%). This new tool, together with the risk of recurrence stratification tools, should facilitate clinicians’ attempts to provide more cost-effective management of DTCs, and this improvement should also have benefits in terms of their patients’ quality of life.
8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2)
Zatelli, Maria ChiaraMembro del Collaboration Group
;Rossi, RobertaMembro del Collaboration Group
;
2018
Abstract
Application of the AJCC-8 criteria can be expected to simplify the staging process for most DTC patients, who will now be classified as ‘younger’. It will also markedly reduce the number of patients with a substantial mortality risk (those with stages III–IV disease, where the DSS-10 is <50–70%). This new tool, together with the risk of recurrence stratification tools, should facilitate clinicians’ attempts to provide more cost-effective management of DTCs, and this improvement should also have benefits in terms of their patients’ quality of life.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lamartina.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
291.84 kB
Formato
Adobe PDF
|
291.84 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
lamartina2017.pdf
accesso aperto
Descrizione: Pre print
Tipologia:
Pre-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
331.64 kB
Formato
Adobe PDF
|
331.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
